Lobeline and cytisine reduce voluntary ethanol drinking behavior in male C57BL/6J mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 1, 2011, Pages 257-264

  Sajja, Ravi K ^a   Rahman, Shafiqur ^a  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Alcohol drinking; Cytisine; Drinking in the dark; Drug addiction; Lobeline; Nicotinic receptor

Indexed keywords

CYSTEINE; LOBELINE; NICOTINIC RECEPTOR; SUCROSE; WATER;

ALCOHOL CONSUMPTION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FLUID INTAKE; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PROTEIN TARGETING;

ALCOHOL DRINKING; ANALYSIS OF VARIANCE; ANIMALS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CHOICE BEHAVIOR; CYSTINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING; ETHANOL; FOOD PREFERENCES; MALE; MICE; MICE, INBRED C57BL; PHENETHYLAMINES; STATISTICS, NONPARAMETRIC; SUCROSE; TIME FACTORS;

EID: 78650964746     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.11.020     Document Type: Article

References (46)

1. Aistrup G.L., Marszalec W., Narahashi T. Ethanol modulation of nicotinic acetylcholine receptor currents in cultured cortical neurons. Mol Pharmacol 1999, 55:39-49.
2. Bell R.L., Eiler B.J., Cook J.B., Rahman S. Nicotinic receptor ligands reduce ethanol intake by high alcohol-drinking HAD-2 rats. Alcohol 2009, 43:581-592.
3. Benwell M.E., Balfour D.J. The influence of lobeline on nucleus accumbens dopamine and locomotor responses to nicotine in nicotine-pretreated rats. Br J Pharmacol 1998, 125:1115-1119.
4. Blomqvist O., Ericson M., Johnson D.H., Engel J.A., Söderpalm B. Voluntary ethanol intake in the rat: effects of nicotinic acetylcholine receptor blockade or subchronic nicotine treatment. Eur J Pharmacol 1996, 314:257-267.
5. Coe J.W., Brooks P.R., Vetelino M.G., Wirtz M.C., Arnold E.P., Huang J., et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005, 48:3474-3477.
6. Dajas-Bailador F., Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signaling. Trends Pharmacol Sci 2004, 25:317-324.
7. Damaj M.I., Patrick G.S., Creasy K.R., Martin B.R. Pharmacology of lobeline, a nicotinic receptor ligand. J Pharmacol Exp Ther 1997, 282:410-419.
8. Dwoskin L.P., Crooks P.A. A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem Pharmacol 2002, 63:89-98.
9. Ericson M., Blomqvist O., Engel J.A., Söderpalm B. Voluntary ethanol intake in the rat and the associated accumbal dopamine overflow are blocked by ventral tegmental mecamylamine. Eur J Pharmacol 1998, 358:189-196.
10. Ericson M., Löf E., Stomberg R., Söderpalm B. The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. J Pharmacol Exp Ther 2009, 329:225-230.
11. Farook J.M., Lewis B., Gaddis J.G., Littleton J.M., Barron S. Lobeline, a nicotinic partial agonist attenuates alcohol consumption and preference in male C57BL/6J mice. Physiol Behav 2009, 97:503-506.
12. Gotti C., Zoli M., Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 2006, 27:482-491.
13. Harrod S.B., Dwoskin L.P., Crooks P.A., Klebaur J.E., Bardo M.T. Lobeline attenuates d-methamphetamine self-administration in rats. J Pharmacol Exp Ther 2001, 298:172-179.
14. Hart N., Rocha A., Miller D.K., Nation J.R. Dose-dependent attenuation of heroin self-administration with lobeline. J Psychopharmacol 2010, 24:51-55.
15. Hendrickson L.M., Zhao-Shea R., Tapper A.R. Modulation of ethanol drinking-in-the-dark by mecamylamine and nicotinic acetylcholine receptor agonists in C57BL/6J mice. Psychopharmacology (Berl) 2009, 204:563-572.
16. Ji D., Gilpin N.W., Richardson H.N., Rivier C.L., Koob G.F. Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like ethanol drinking in rats. Behav Pharmacol 2008, 19:1-12.
17. Kamdar N.K., Miller S.A., Syed Y.M., Bhayana R., Gupta T., Rhodes J.S. Acute effects of naltrexone and GBR 12909 on ethanol drinking-in-the-dark in C57BL/6J mice. Psychopharmacology (Berl) 2007, 192:207-217.
18. Kamens H.M., Anderson J., Picciotto M.R. Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice. Psychopharmacology (Berl) 2010, 208:613-626.
19. Klink R., de Kerchove d' Exaerde A., Zoli M., Changeux J.P. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci 2001, 21:1452-1463.
20. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35:217-238.
21. Kuzmin A., Jerlhag E., Liljequist S., Engel J.A. Effects of subunit selective nAChR receptors on operant ethanol self-administration and relapse-like ethanol-drinking behavior. Psychopharmacology (Berl) 2009, 203:99-108.
22. Larsson A., Engel J.A. Neurochemical and behavioral studies on ethanol and nicotine interactions. Neurosci Biobehav Rev 2004, 27:713-720.
23. Lê A.D., Corrigall W.A., Harding J.W., Juzytsch W., Li T.K. Involvement of nicotinic receptors in alcohol self-administration. Alcohol Clin Exp Res 2000, 24:155-163.
24. Mihalak K.B., Carroll F.I., Luetje C.W. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 2006, 70:801-805.
25. 3H] dopamine overflow from rat striatal slices and nicotine-evoked (86)Rb(+) efflux from thalamic synaptosomes. Neuropharmacology 2000, 39:2654-2662.
26. Miller D.K., Lever J.R., Rodvelt K.R., Baskett J.A., Will M.J., Kracke G.R. Lobeline, a potential pharmacotherapy for drug addiction, binds to mu opioid receptors and diminishes the effects of opioid receptor agonists. Drug Alcohol Depend 2007, 89:282-291.
27. Minuer Y.S., Somenzi O., Picciotto M.R. Cytisine, a partial agonist of high affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology 2007, 52:1256-1262.
28. Minuer Y.S., Eibl C., Young G., Kochevar C., Papke R.L., Gundisch D., et al. Cytisine-based partial agonists as novel antidepressant compounds. J Pharmacol Exp Ther 2009, 329:377-386.
29. Mushoff M., Madea B. Fatal cytisine intoxication and analysis of biological samples using LC-MS/MS. Forensic Sci Int 2009, 186:e1-e4.
30. Owens J.C., Balogh S.A., McClure-Begley T.D., Butt C.M., Labarca C., Lester H.A., et al. Alpha 4 beta 2* nicotinic acetylcholine receptors modulate the effects of ethanol and nicotine on the acoustic startle response. Alcohol Clin Exp Res 2003, 27:1867-1875.
31. Papke R.L., Heinemann S.F. Partial agonist properties of cytisine on neuronal nicotinic receptors containing beta2 subunit. Mol Pharmacol 1994, 45:142-149.
32. Parker M.J., Beck A., Luetje C.W. Neuronal nicotinic receptor β2 and β4 subunits confer large differences in agonist binding affinity. Mol Pharmacol 1998, 54:1132-1139.
33. Picciotto M.R., Addy N.A., Mineur Y.S., Brunzell D.H. It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol 2008, 84:329-342.
34. Rahman S., Lopez-Hernandez G.Y., Corrigall W.A., Papke R.L. Neuronal nicotinic receptors as brain targets for pharmacotherapy of drug addiction. CNS Neurol Disord Drug Targets 2008, 7:422-441.
35. Rahman S., Neugebauer N.M., Zhang Z., Crooks P.A., Dwoskin L.P., Bardo M.T. The novel nicotinic receptor antagonist N,N'-dodecane-1, 12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens. Eur J Pharmacol 2008, 601:103-105.
36. Reavill C., Walther B., Stolerman I.P., Testa B. Behavioral and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology 1990, 29:619-624.
37. Rezvani A.H., Overstreet D.H., Yang Y., Maisonneuve I.M., Bandarage U.K., Kuehne M.E., et al. Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats. Pharmacol Biochem Behav 1997, 58:615-619.
38. Rhodes J.S., Best K., Belknap J.K., Finn D.A., Crabbe J.C. Evaluation of a simple model of ethanol drinking to intoxication in C57BL/6J mice. Physiol Behav 2005, 84:53-63.
39. Rollema H., Hajos M., Seymour P.A., Kozak R., Majchrzak M.J., Guanowsky V., et al. Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol 2009, 78:813-824.
40. Sajja R., Dwivedi C., Rahman S. Nicotinic ligands modulate ethanol-induced dopamine function in mice. Pharmacology 2010, 86:168-173.
41. Sparta D.R., Fee J.R., Hayes D.M., Knapp D.J., MacNeil D.J., Thiele T.E. Peripheral and central administration of a selective neuropeptide Y Y1 receptor antagonist suppresses ethanol intake by C57BL/6J mice. Alcohol Clin Exp Res 2004, 28:1324-1330.
42. Steensland P., Simms J.A., Holgate J., Richards J.K., Bartlett S.E. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci U S A 2007, 104:12518-12523.
43. 3H] dopamine uptake. J Pharmacol Exp Ther 1997, 280:1432-1444.
44. Tizabi Y., Bai L., Copeland R.L., Taylor R.E. Combined effects of systemic alcohol and nicotine on dopamine release in the nucleus accumbens shell. Alcohol Alcohol 2007, 42:413-416.
45. Tutka P., Zatoński W. Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacol Rep 2006, 53:777-798.
46. Yoneyama N., Crabbe J.C., Ford M.M., Murillo A., Finn D.A. Voluntary ethanol consumption in 22 inbred mouse strains. Alcohol 2008, 42:149-160.